You are here

soticlestat

Takeda takes $140M charge on failed epilepsy drug, while touting continued FDA potential

Fierce Biotech

Wed, 07/31/24 - 10:53 am

Takeda flunks pivotal epilepsy tests but mulls path to market for Ovid-partnered prospect

Fierce Biotech

Mon, 06/17/24 - 11:29 am

clinical trials

Ovid Therapeutics

Dravet syndrome